TickerFacts.

HCW Biologics Inc. (HCWB): Long-Term Debt

Annual figures by period end, from SEC filings.

$0
As of 2025-12-31
$7.38M2021-12-31: $02022-12-31: $6.41M2023-12-31: $6.30M2024-12-31: $7.38M2025-12-31: $0$0
2021-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$0-100.0%2026-03-31, Balance as of period end
2024-12-31$7.38M+17.0%2026-03-31, Balance as of period end
2023-12-31$6.30M-1.6%2025-03-28, Balance as of period end
2022-12-31$6.41Mn/a2024-05-15, Balance as of period end
2021-12-31$0n/a2023-03-28, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
HCW Biologics Inc. (HCWB)2025-12-31$0-100.0%
Altimmune, Inc. (ALT)2025-12-31$34.29Mn/a
Clene Inc. (CLNN)2025-12-31$17.79Mn/a
Scienture Holdings, Inc. (SCNX)2024-12-31$2.90Mn/a
Yarrow Bioscience, Inc. (YARW)2025-12-31$0n/a
BioXcel Therapeutics, Inc. (BTAIQ)2025-12-31$109.59M+6.9%
60 Degrees Pharmaceuticals, Inc. (SXTP)2025-12-31$150.0K0.0%
China SXT Pharmaceuticals, Inc. (SXTC)2025-03-31$807.2K+27.8%
Northwest Biotherapeutics Inc (NWBO)2025-12-31$60.04M-4.2%

Compare HCWB, ALT, CLNN, SCNX side by side · Screen every company in Pharmaceutical Preparations ↗